SNIPER(ABL)-039

• UNSPSC Description:

  SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, cIAP1, cIAP2, XIAP, respectively[1].

• Target Antigen:

  Bcr-Abl; SNIPERs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sniper-abl-039.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C(NC(C2=CN=C(NC3=CC(N4CCN(C(COCCOCCOCCOC5=CC(C(C6=CSC([C@H]7N(C([C@H](C8CCCCC8)NC([C@H](C)NC)=O)=O)CCC7)=N6)=O)=CC=C5)=O)CC4)=NC(C)=N3)S2)=O)C(Cl)=CC=C1

• Molecular Weight:

  1114.77

• References & Citations:

  [1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2222354-29-0